HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, vol.15, issue.Suppl, pp.69-78, 2014. ,
DOI : 10.1111/liv.12423
Treatment of Hepatitis C, JAMA, vol.312, issue.6, pp.631-671, 2014. ,
DOI : 10.1001/jama.2014.7085
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome, Journal of Clinical Investigation, vol.124, issue.8, pp.3352-63, 2014. ,
DOI : 10.1172/JCI75938DS1
Restoration of HCV-specific CD8+ T cell function by interferon-free therapy, Journal of Hepatology, vol.61, issue.3, pp.538-581, 2014. ,
DOI : 10.1016/j.jhep.2014.05.043
Continued value in understanding viral kinetic decline during interferon-free therapy for HCV. Liver international: official journal of the International Association for the Study of the Liver, pp.295-301, 2015. ,
Hepatitis C can be cured globally, but at what cost?, Science, vol.345, issue.6193, 2014. ,
DOI : 10.1126/science.1257737
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C, Hepatology, vol.194, issue.Suppl 2, p.2579317, 2008. ,
DOI : 10.1002/hep.22500
Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes, Journal of Hepatology, vol.59, issue.4, pp.701-709, 2013. ,
DOI : 10.1016/j.jhep.2013.06.001
The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection, Journal of Hepatology, vol.47, issue.5, pp.632-673, 2007. ,
DOI : 10.1016/j.jhep.2007.04.009
The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection, Journal of Viral Hepatitis, vol.25, issue.0, pp.675-87, 2007. ,
DOI : 10.1016/S0168-8278(02)00429-4
Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection, Journal of Hepatology, vol.55, issue.3, pp.545-53, 2011. ,
DOI : 10.1016/j.jhep.2010.12.033
Positioning of leukocyte subsets in the portal and lobular compartments of hepatitis C virus-infected liver correlates with local chemokine expression, Journal of Gastroenterology and Hepatology, vol.196, issue.4, pp.860-869, 2014. ,
DOI : 10.1111/jgh.12462
Association of pretreatment serum interferon ?? inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C, Gut, vol.55, issue.3, pp.374-383, 2005. ,
DOI : 10.1136/gut.2005.074062
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection, Hepatology, vol.38, issue.6, pp.1617-1642, 2006. ,
DOI : 10.1002/hep.21407
Interferon (IFN)-gammainducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection, J Infect Dis, vol.194507307, issue.7, pp.895-903, 2006. ,
Quantitation of pretreatment serum interferon-??-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response, Hepatology, vol.8, issue.1, pp.14-22, 2011. ,
DOI : 10.1002/hep.24056
Serum Level of IP-10 Increases Predictive Value of IL28B Polymorphisms for Spontaneous Clearance of Acute HCV Infection, Gastroenterology, vol.142, issue.1, pp.78-85, 2012. ,
DOI : 10.1053/j.gastro.2011.09.039
Discrimination of agonist and antagonist forms of CXCL10 in biological samples, Clinical & Experimental Immunology, vol.110, issue.1, pp.137-185, 2012. ,
DOI : 10.1111/j.1365-2249.2011.04488.x
URL : https://hal.archives-ouvertes.fr/pasteur-01402047
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV, Journal of Clinical Investigation, vol.121, issue.1, pp.308-325, 2011. ,
DOI : 10.1172/JCI40594DS1
URL : https://hal.archives-ouvertes.fr/pasteur-01402089
Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection, Hepatology, vol.22, issue.2, pp.487-96, 2014. ,
DOI : 10.1002/hep.27139
URL : https://hal.archives-ouvertes.fr/pasteur-01384520
CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients, Cytokine, vol.63, issue.2, pp.105-117, 2013. ,
DOI : 10.1016/j.cyto.2013.04.016
URL : https://hal.archives-ouvertes.fr/pasteur-01385516
Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection, PLoS ONE, vol.22, issue.2, p.3577643, 2013. ,
DOI : 10.1371/journal.pone.0056991.t007
Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations, Nature Biotechnology, vol.8, issue.6, pp.595-604, 2010. ,
DOI : 10.1038/nbt.1641
Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics, JAMA, vol.310, issue.8 ,
DOI : 10.1001/jama.2013.109309
Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse, Annals of Internal Medicine, vol.161, issue.9, pp.634-642, 2014. ,
DOI : 10.7326/M14-1211